Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Early Stage RRMS (ENSEMBLE)
NCT03085810Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, open-label trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Roche. Primary endpoints: Time to Onset of Confirmed Disability Progression at 4 years, Confirmed Disability Improvement at 192 weeks and 5 more. Started Mar 2017; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03085810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085810.